149 related articles for article (PubMed ID: 36484341)
1. Population pharmacokinetics and exposure-response analyses of daratumumab plus pomalidomide/dexamethasone in relapsed or refractory multiple myeloma.
Dosne AG; Li X; Luo MM; Nnane I; Dimopoulos MA; Terpos E; Sonneveld P; Kampfenkel T; Carson R; Amin H; Perez Ruixo J; Zhou H; Sun YN; Xu Y
Br J Clin Pharmacol; 2023 May; 89(5):1640-1655. PubMed ID: 36484341
[TBL] [Abstract][Full Text] [Related]
2. Subcutaneous daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (APOLLO): extended follow up of an open-label, randomised, multicentre, phase 3 trial.
Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Kampfenkel T; Liu W; Wang J; Kosh M; Tran N; Carson R; Sonneveld P
Lancet Haematol; 2023 Oct; 10(10):e813-e824. PubMed ID: 37793772
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetic and exposure-response analyses of elotuzumab plus pomalidomide and dexamethasone for relapsed and refractory multiple myeloma.
Ide T; Osawa M; Sanghavi K; Vezina HE
Cancer Chemother Pharmacol; 2022 Jan; 89(1):129-140. PubMed ID: 34825942
[TBL] [Abstract][Full Text] [Related]
4. Indirect Treatment Comparison of Daratumumab, Pomalidomide, and Dexamethasone Versus Standard of Care in Patients with Difficult-to-Treat Relapsed/Refractory Multiple Myeloma.
He J; Berringer H; Heeg B; Ruan H; Kampfenkel T; Dwarakanathan HR; Johnston S; Mendes J; Lam A; Bathija S; Mackay EK
Adv Ther; 2022 Sep; 39(9):4230-4249. PubMed ID: 35876974
[TBL] [Abstract][Full Text] [Related]
5. Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial.
Dimopoulos MA; Terpos E; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Baldini L; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Ahmadi T; Ukropec J; Kampfenkel T; Schecter JM; Qiu Y; Amin H; Vermeulen J; Carson R; Sonneveld P;
Lancet Oncol; 2021 Jun; 22(6):801-812. PubMed ID: 34087126
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.
Xu XS; Dimopoulos MA; Sonneveld P; Ho PJ; Belch A; Leiba M; Capra M; Gomez D; Medvedova E; Iida S; Min CK; Schecter J; Jansson R; Zhang L; Sun YN; Clemens PL
Adv Ther; 2018 Nov; 35(11):1859-1872. PubMed ID: 30374808
[TBL] [Abstract][Full Text] [Related]
7. Population Pharmacokinetics and Exposure Response Analysis of Pomalidomide in Subjects With Relapsed or Refractory Multiple Myeloma From the Novel Combination Treatment of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone.
Li Y; Kassir N; Wang X; Palmisano M; Zhou S
J Clin Pharmacol; 2020 Aug; 60(8):1061-1075. PubMed ID: 32168381
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
[TBL] [Abstract][Full Text] [Related]
9. Population Pharmacokinetics and Exposure-Response Modeling of Daratumumab Subcutaneous Administration in Patients With Light-Chain Amyloidosis.
Luo MM; Zhu PP; Nnane I; Xiong Y; Merlini G; Comenzo RL; Kastritis E; Wechalekar AD; Weiss BM; Tran N; Qin X; Vermeulen J; Sharma A; Sun YN; Zhou H
J Clin Pharmacol; 2022 May; 62(5):656-669. PubMed ID: 34708423
[TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes from the APOLLO trial.
Terpos E; Dimopoulos MA; Boccadoro M; Delimpasi S; Beksac M; Katodritou E; Moreau P; Pompa A; Symeonidis A; Bila J; Oriol A; Mateos MV; Einsele H; Orfanidis I; Gries KS; Fastenau J; Liu K; He J; Kampfenkel T; Qiu Y; Amin H; Carson R; Sonneveld P
Am J Hematol; 2022 Apr; 97(4):481-490. PubMed ID: 35089607
[TBL] [Abstract][Full Text] [Related]
11. Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses.
Xu XS; Moreau P; Usmani SZ; Lonial S; Jakubowiak A; Oriol A; Krishnan A; Bladé J; Luo M; Sun YN; Zhou H; Nnane I; Deraedt W; Qi M; Ukropec J; Clemens PL
Adv Ther; 2020 Apr; 37(4):1464-1478. PubMed ID: 32078124
[TBL] [Abstract][Full Text] [Related]
12. Daratumumab in Indian patients with relapsed and refractory multiple myeloma: a prospective, multicenter, phase IV study.
Kumar L; Melinkeri S; Ganesan P; Kumar J; Biswas G; Kilara N; Pathalingappa H; Prasad S; Jain M; Mishra SK; Prasad S; Boyella PK; Sahoo RK; Bondarde S; Shah S; Rege M; Deb U; Korde T; Dixit J
Future Oncol; 2024 Feb; 20(4):191-205. PubMed ID: 38116642
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive overview of daratumumab and carfilzomib and the recently approved daratumumab, carfilzomib and dexamethasone regimen in relapsed/refractory multiple myeloma.
Richard S; Jagannath S; Cho HJ; Parekh S; Madduri D; Richter J; Chari A
Expert Rev Hematol; 2021 Jan; 14(1):31-45. PubMed ID: 33331794
[No Abstract] [Full Text] [Related]
14. Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series.
Djebbari F; Poynton M; Sangha G; Anderson L; Maddams R; Eyre TA; Vallance G; Basu S; Ramasamy K
Hematology; 2022 Dec; 27(1):204-207. PubMed ID: 35134321
[No Abstract] [Full Text] [Related]
15. Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma.
Iida S; Ichinohe T; Shinagawa A; Suzuki K; Takezako N; Aoki M
Int J Hematol; 2018 Apr; 107(4):460-467. PubMed ID: 29260507
[TBL] [Abstract][Full Text] [Related]
16. Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14).
Bahlis NJ; Baz R; Harrison SJ; Quach H; Ho SJ; Vangsted AJ; Plesner T; Moreau P; Gibbs SD; Coppola S; Yang X; Al Masud A; Ross JA; Bueno O; Kaufman JL
J Clin Oncol; 2021 Nov; 39(32):3602-3612. PubMed ID: 34388020
[TBL] [Abstract][Full Text] [Related]
17. [Efficacy and safety of daratumumab in patients with relapsed/refractory multiple myeloma].
Zhao AL; Tang WJ; Li Y; Liao Y; Li H; Wang J; Shen K; Yang YF; Xu J; Zhang L; Zheng YH; Niu T
Zhonghua Yi Xue Za Zhi; 2022 Nov; 102(41):3304-3311. PubMed ID: 36319183
[No Abstract] [Full Text] [Related]
18. Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab.
Kim K; Phelps MA
Clin Pharmacokinet; 2023 Jun; 62(6):789-806. PubMed ID: 37129750
[TBL] [Abstract][Full Text] [Related]
19. Pomalidomide, dexamethasone, and daratumumab in Japanese patients with relapsed or refractory multiple myeloma after lenalidomide-based treatment.
Matsue K; Sunami K; Matsumoto M; Kuroda J; Sugiura I; Iwasaki H; Chung W; Kuwayama S; Nishio M; Lee K; Iida S
Int J Hematol; 2022 Jul; 116(1):122-130. PubMed ID: 35429329
[TBL] [Abstract][Full Text] [Related]
20. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.
Chari A; Suvannasankha A; Fay JW; Arnulf B; Kaufman JL; Ifthikharuddin JJ; Weiss BM; Krishnan A; Lentzsch S; Comenzo R; Wang J; Nottage K; Chiu C; Khokhar NZ; Ahmadi T; Lonial S
Blood; 2017 Aug; 130(8):974-981. PubMed ID: 28637662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
